Companies find it challenging to justify long-term, risky R&D investments — particularly in science-based fields such as biotechnology. Maybe it’s time to consider a different financing model.
Companies find it challenging to justify long-term, risky R&D investments — particularly in science-based fields such as biotechnology. Maybe it’s time to consider a different financing model.